New drug indication approval - February 2024

Product Name	RINVOQ EXTENDED-RELEASE TABLET 15MG, RINVOQ EXTENDED-RELEASE TABLETS 30 MG, RINVOQ EXTENDED-RELEASE TABLET 45MG
Active Ingredient (Strength)	Upadacitinib Hemihydrate eqv Upadacitinib(15mg), Upadacitinib Hemihydrate eqv Upadacitinib(30mg), Upadacitinib Hemihydrate eqv Upadacitinib(45mg)
Product Registrant	ABBVIE PTE. LTD.
Date of Approval	16/02/2024
Indications: Crohn’s Disease RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Published: 7 May 2024

New Drug Indication Approvals